

NIH Public Access

Author Manuscript

Aquaculture. Author manuscript; available in PMC 2012 October 1.

Published in final edited form as:

Aquaculture. 2011 October 1; 319(3-4): 342–346. doi:10.1016/j.aquaculture.2011.07.021.

Tol2-mediated transgenesis in tilapia (Oreochromis niloticus)

Koji Fujimura^{a,b} and Thomas D. Kocher^{a,*}

^aDepartment of Biology, University of Maryland, 1210 Biology/Psychology Building, University of Maryland, College Park, Maryland 20742, USA

Abstract

The Nile tilapia (*Oreochromis niloticus*) is an important species in aquaculture and an excellent model system for laboratory studies. Functional genetic analysis using this species has been difficult because existing methods for producing transgenics are inefficient. Here we show that the *Tol2* transposon system can be used to create transgenic tilapia with high efficiency. We constructed a line that is transgenic for GFP under control of a *Xenopus* elongation factor 1α (EF1 α) promoter. The germline transmission rate of the *Tol2* construct to the first generation was about 30%, which is much higher than conventional methods. GFP expression was strong and ubiquitous in the embryos. Application of the *Tol2* system for constructing transgenics in tilapia and related species will promote research in many areas, but will be especially useful for studies of evolutionary developmental biology in the cichlid fishes of East Africa.

Keywords

Nile tilapia Oreochromis niloticus; transgenic; EF1a; GFP; Tol2

1. Introduction

The Nile tilapia *Oreochromis niloticus* (Pisces: Cichlidae) is a globally important aquaculture species (FAO, 2008). It is also an excellent laboratory model for questions ranging from physiology (McCormick et al., 1992; Farrell and Campana, 1996) and endocrinology (Parhar et al., 2000; Strüssmann and Nakamura, 2002), to genomic biology and molecular genetics (Majumdar and McAndrew, 1986; Kocher et al., 1998; Oliveira and Wright, 1998; Lee et al., 2005; Katagiri et al., 2005; Santini and Bernardi, 2005). Tilapia breed year-round (2–3 week spawning cycle), are highly fecund (hundreds of eggs in a clutch), and have a short generation period (six months) (Fujimura and Okada, 2007). They are externally fertilized and it is easy to obtain one-cell stage eggs by artificial fertilization (Fujimura and Okada, 2007).

Transgenic tilapias have been established, especially for the purpose of enhancing the growth rate of tilapia in aquaculture, for more than 20 years (Brem et al., 1988). The usual method is the random integration of plasmid DNA which has been introduced into fertilized eggs by microinjection. However, in the conventional method, the frequency of germline

^{© 2011} Elsevier B.V. All rights reserved.

Corresponding Author: Telephone: +1-301-405-4496, Fax: +1-301-314-9358, tdk@umd.edu.

^bPresent address: Department of Anatomy, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105-8461, Japan.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

transmission of the injected DNA has been low. Maclean et al. (2002) summarize traditional approaches in which the rate of germline transmission in tilapia is 0.1 - 10%.

Transposable elements have been an invaluable tool for transgenesis and mutagenesis in many organisms (Ivics et al., 2009). The *Tol2* transposable element has been particularly useful for generating transgenic zebrafish (Kawakami, 2007). *Tol2* was originally identified in the genome of the Japanese medaka fish, *Oryzias latipes* (Koga et al., 1996). An autonomous member of the *Tol2* element, which encodes a gene for a fully functional transposase that is capable of catalyzing transposition, has been identified (Kawakami et al., 1998; Kawakami and Shima, 1999). Furthermore, Kawakami et al. (2000, 2004) developed a two-component transposition system in zebrafish, in which a transposase mRNA, are co-injected into the fertilized eggs. In the egg, the construct is excised from the donor plasmid and integrated into the genome of germ cells. The germline transmission frequency is typically very high, and the *Tol2* system is now widely used for transgenesis of not only zebrafish, but also several model animals, from frogs (Johnson Hamlet et al., 2006) to flies (Urasaki et al., 2008).

Despite this broad success, there is concern that endogenous transposase activity might limit the utility of the *Tol2* system in other fish species. Here we show that the *Tol2* system can be used to create transgenic tilapia, by demonstrating germline transmission of transgenes with strong and ubiquitous expression of GFP under the control of a *Xenopus* EF1 α promoter.

2. Materials and methods

2.1. Animals

The parental Nile tilapia used in this work were transferred from the Tokyo Institute of Technology (Yokohama, Japan) to the University of Maryland (College Park MD, USA). Each of the adult fish was maintained under constant conditions $(28 \pm 1^{\circ}C, 10h \text{ dark}/14h \text{ light cycle})$ in a 40-liter tank system, through which fresh water was circulated. The fish were fed three times daily with granulated commercial foods.

Developmental stages were determined according to Fujimura and Okada (2007). We also used hours post-fertilization (hpf), and days post-fertilization (dpf) to supply more detailed staging information.

2.2. Microinjection

The pT2AL200R150G plasmid (Urasaki et al., 2006) was used in this work. The plasmid contains minimal elements for Tol2 transposition as well as the green fluorescent protein (GFP) expression cassette, namely the *Xenopus* elongation factor 1α (EF1 α) enhancerpromoter, the rabbit β -globin intron, the enhanced GFP gene, and the SV40 poly(A) signal. The plasmid was electroporated into E. coli strain DH10B (Invitrogen, Carlsbad CA, USA), cultured, and prepared using the Qiagen Plasmid mini kit (Qiagen, Duesseldorf, Germany). The plasmid solution was further purified using the QIAquick PCR purification kit (Qiagen), and diluted to a stock concentration of 125 ng/ μ l. The transposase mRNA was synthesized using pCS-TP and mMessage mMachine Sp6 Kit (Ambion, Austin TX, USA) following Kawakami et al. (2004). The RNA solution was purified using Qiagen RNeasy kit (Qiagen), and diluted to a stock concentration of 175 ng/µl. Phenol red (2% stock in H₂O, Sigma-Aldrich, St. Louis MO, USA) was used to visualize the solution during injecting. Five µl of injection solution was prepared by mixing each stock solution and RNase-free water. For transposase (+) we used 25 ng/µl plasmid, 35 ng/µl RNA, 0.2% phenol red. For transposase (-) we used 25 ng/ul plasmid, 0.2% phenol red. We filled pipettes from the back-end using microloader pipette tips (Eppendorf, Hamburg, Germany).

Fujimura and Kocher

The transgenic tilapia were produced by microinjecting eggs at the one-cell stage. Artificially fertilized eggs were obtained as described in Fujimura and Okada (2007). The eggs were kept in a Petri dish in embryo medium (14.97 mM NaCl, 0.50mM KCl, 1.31mM CaCl₂, 0.99mM MgSO₄, 0.15mM KH₂PO₄, 0.05mM Na₂HPO₄, 0.07mM NaHCO₃; Fisher et al., 2006). Each egg was held with sharp forceps while injecting. Needles (GD-1; Narishige, Tokyo, Japan) were pulled in a P-97 puller (Sutter Instrument, Novato CA, USA). Before injection, they were carefully broken using forceps while viewing under a microscope. Several nanoliters of the solution were injected into the cell through the micropyle (Brem et al., 1988; Rahman and Maclean, 1992), using a PLI-100 injector (Harvard Apparatus, Holliston MA, USA) and an HI-7 pipette holder (Narishige).

The injected eggs were cultured in round-bottom 200ml-flasks into which recirculating system water was gently supplied. The three embryos that had the strongest GFP expression at 5 dpf were chosen as the first generation transgenic fish (G_0). Around 8 dpf, the three G_0 larvae were each moved to a separate 40-liter tank in the system, and kept under the same condition as described above for the parental fish. Each of the three was female, and they started to spawn eggs after 6 months. Eggs from the three G_0 transgenic females and sperm from a non-transgenic male were used for production of the second generation (G_1). The resultant G_1 embryos were segregated in two groups according to their GFP expression; GFP (+) and GFP (-).

2.3. Excision assay of Tol2

The excision assay was performed as described for zebrafish (Kawakami, 2004) with some modifications. The DNA samples were prepared from the injected embryos of Stage 9 (2 dpf, 24 hpf), Stage 13 (3 dpf, 48 hpf), and Stage 15 (4 dpf, 72 hpf), and isolated by phenol-chloroform extraction. The PCR product was amplified using the primers T2AexL-2 (5'-ACC CTC ACT AAA GGG AAC AAA AG-3') and T2AexR-2 (5'-GTG CGG GCC TCT TCG CTA TTA C-3'), as described in Urasaki et al. (2006).

2.4. GFP observation

GFP expression in embryos was examined using a fluorescence-equipped dissecting microscope MZ16FA (Leica Microsystems, Wetzlar, Germany) with GFP filter sets (Leica GFP3, excitation 470/40 nm band-pass, emission 525/50 nm band-pass). Images were captured using a digital camera DFC420 (Leica Microsystems).

3. Results

3.1. Tol2 system in Nile tilapia

We tested whether the *Tol2* transposon system is active in Nile tilapia by performing a PCRbased excision assay. We injected circular DNA plasmids of pT2AL200R150G, with or without *in vitro* synthesized mRNA of medaka transposase into tilapia eggs. DNA was isolated from the injected embryos and assayed by PCR. If the *Tol2* transposase excised the *Tol2* constructs from the plasmid, a PCR product of ~272 bp would be amplified from the remnant plasmid. The PCR product was not detected when only the plasmid was injected (0/7 embryos), indicating that tilapia did not express an endogenous transposase that might be a concern for this method. The PCR product was detected in six of 18 embryos injected with both of the plasmid and transposase mRNA, demonstrating that a transposasedependent *Tol2* excision did occur. After cloning and sequencing the PCR products, we confirmed that most clones had DNA sequences consistent with clean excision of the *Tol2* element. We also tested whether the *Tol2* construct containing EF1 α promoter and GFP was integrated into the genomic DNA after excision. We observed GFP expression during development of the injected embryos (Stage 15; Fig. 1). In all of the embryos injected with only the plasmid (27 survivors; Fig. 1a, b), no GFP signal was observed. However, in the embryos injected with both the plasmid and transposase mRNA (Fig. 1c, d), mosaic GFP expression was observed in the entire body. Although the survival rate of the injected embryos was low (44.4%), the GFP-positive rate in 138 survivors was 67.4%. These results imply that the *Tol2* transposase promotes the genomic integration of the *Tol2* construct at an early developmental stage.

3.2. Germline transmission of Tol2 in Nile tilapia

We further tested whether Tol2 can transpose into the germ lineage of Nile tilapia. In this study, we chose the three G₀ embryos (TG14-1, 2, 3 in Table 1) that had strong GFP signals. The three were raised to adult in six months, and all three were female. We examined GFP expression in 2,815 G₁ embryos obtained by crosses between a non-transgenic male and the three transgenic females. GFP-positive expression was observed in 29.1% of the G₁ embryos (Table 1).

3.3. GFP observation of transgenic green tilapia

GFP expression in the G_1 embryos varied in intensity, but there was no indication that this was related to the founder lineage (Fig. 2). Strong and ubiquitous GFP expression (GFP ++) was observed in 43.9% of the GFP-positive embryos (Fig. 2a, b). Weak or mosaic GFP expression (GFP +) was observed in 56.1% of the GFP-positive embryos (Fig. 2c–f).

In the GFP ++ G_1 embryos, GFP signals were observed from the one-cell stage onward (Stage 1; Fig. 3a, b). As a result of convergence and extension movements over the yolk, epiboly began to spread the blastoderm across the yolk at Stage 9. The GFP signals were observed in the cells over the yolk, and the developing embryonic shield was visible with slightly stronger GFP intensity (Stage 9; Fig. 3c, d). At Stage 12, strong GFP expression was observed in the entire body of embryo (Stage 12; Fig. 3e, f). Somitogenesis can be observed along the body axis.

The GFP expression continued in the entire body at later stages of development (Fig. 4). At Stage 15 (Fig. 4a) and Stage 17 (Fig. 4b), strong expression was found in the eyes, optic tectum, and pharyngeal region. Expression was also observed at the myoseptum and pectoral fin buds. After Stage 18 (Fig. 4c), strong expression was found in the developing muscle of the body region. At Stage 19 (Fig. 4d) and Stage 21 (Fig. 4e), strong expression was found in the 'undifferentiated white tissue' (Fujimura and Okada, 2007; arrows in Fig. 4d, e) between the yolk and body. Expression in this tissue could be also observed in the earlier stages (arrows in Fig. 4a, b, c). At Stage 21, the signals became weaker as the pigment cells covered the head region and body wall and obscure the signal (Fig. 4e).

4. Discussion

In this study, we demonstrated that the *Tol2* system is an effective tool for generating transgenic Nile tilapia. We observed a germline transmission rate of the *Tol2* construct to the G_1 of about 30%. This rate compares favorably with the rates from injection of conventional plasmids, which generally vary from 0.1 - 10% (for review, Maclean et al., 2002; also see Alam et al., 1996; Rahman et al., 1997, 1998; Kobayashi et al., 2007; Farlora et al., 2009). Under the conditions of our experiment, no integration was observed when circular DNA plasmids were injected without transposase mRNA, as evidenced by the lack of GFP signal (Fig. 1). The rate of integration without transposase might be higher if linearized plasmids

were used, because linearized form have several times more integration rates than circular one (Chourrout et al. 1986), but would still be much lower than the transposase-mediated integration.

We observed some variation in the intensity of GFP expression (Fig. 2). This variation might be due to position effects at the integration site (Wilson et al., 1990) or variation in copy number (Rahman et al., 2000). Similar variation was found in transgenic *Xenopus* made using the *Tol2* system (Johnson Hamlet et al., 2006).

The *Xenopus* EF1 α promoter was used in this study. EF1 α protein promotes guanosine triphosphate (GTP)-dependent binding of aminoacyl-tRNA to ribosome during eukaryotic protein synthesis, and it is ubiquitously expressed in all types of cells (Negrutskii and Elskaya, 1998). Therefore, the EF1 α promoter has been used to generate animals with ubiquitous expression of a transgene (Udvadia and Linney, 2003). Our results show that the *Xenopus* EF1 α promoter drives ubiquitous expression in Nile tilapia, as it does in zebrafish (Urasaki et al., 2006).

As shown in Figure 3, the GFP expression was first observed at the one-cell stage. Kinoshita et al. (2000) clearly showed that the expression pattern of GFP depends on the sex of the transgenic parent in EF1 α /GFP transgenic medaka. In their study, GFP expression was first observed at the early gastrula stage when crossing transgenic males with non-transgenic females, indicating that the expression is zygotic. On the other hand, GFP expression was first observed at the one-cell stage when crossing transgenic females with non-transgenic males, indicating that the expression is maternal. Consistent with these expectations, the one-cell stage embryos produce by the three G₀ tilapia females in this study showed GFP signals that were probably due to maternal expression.

As shown in Figures 3 and 4, these transgenic lines under the control of the *Xenopus* EF1 α have strong and ubiquitous GFP expression in living embryos. This improves visualization of early development in tilapia, which is sometimes difficult due to the large translucent yolk. In this regard, our GFP transgene is an improvement over previous constructs using lacZ expression, which is usually visualized after fixation and staining (Alam et al., 1996). Transgenic tilapia expressing GFP under the control of a β -actin promoter showed weak and mosaic expression during development (Farlora et al., 2009). In contrast, the *Xenopus* EF1 α / eGFP construct used in our work gave strong and ubiquitous GFP signals. We are currently developing a G₂ generation from the GFP ++ G₁ progenies for use in developmental biology experiments, including cell transplantation.

The transgenic technology we have demonstrated could be applied in aquaculture to produce fish with improved genetic traits. For production of genetically modified fish in aquaculture, it is desired that gene constructs are designed with using sequences from the same or related fish species, and avoiding as much as possible the use of sequences of viral origin (Maclean et al., 2002). Therefore, there is a great potential for transgenic tilapia using the Tol2 system, which is originally derived from the medaka fish.

However, we believe this technology will be best used for basic biological research. The ability to modulate gene expression will enhance the analysis of gene networks controlling growth rate, disease resistance, salinity tolerance, temperature tolerance, sex determination, and reproduction. Several gene promoters of Nile tilapia have already been characterized (Maclean et al., 2002), and many more will be available with the completion of the tilapia genome sequence (www.broadinstitute.org/models/tilapia). It should be possible now to use the *Tol2* system to construct a variety of transgenic tilapia for basic research.

Moreover, we hope our work will promote studies of evolutionary developmental biology in African cichlids. Cichlids in the East African Great Lakes are famous as spectacular examples of explosive adaptive radiation (Fryer and Iles, 1972; Kocher, 2004), particularly in their trophic morphologies (Albertson and Kocher, 2006), pigmentation (Roberts et al., 2009) and visual sensitivities (Hofmann et al., 2009). Recent studies suggest that changes in gene expression during development are more important than changes in gene coding sequence (Albertson et al., 2005; Kijimoto et al., 2005). In the context of a well-characterized developmental staging system (Fujimura and Okada, 2007, 2008a, 2008b), a highly efficient transgenic technology will facilitate investigations of the regulatory variants responsible for the dramatic evolutionary radiation of these fishes.

Acknowledgments

The authors thank Drs. Norihiro Okada and Masato Nikaido of Tokyo Institute of Technology for the *O. niloticus* parental stocks. Dr. Koichi Kawakami of National Institute of Genetics graciously supplied the plasmid stocks. This work was supported by grant R01HD058635 from the National Institutes of Health.

References

- Alam MS, Popplewell A, Maclean N. Germ line transmission and expression of a *lacZ* containing transgene in tilapia (*Oreochromis niloticus*). Transgenic Res. 1996; 5:87–95.
- Albertson RC, Streelman JT, Kocher TD, Yelick PC. Integration and evolution of the cichlid mandible: the molecular basis of alternate feeding strategies. Proc Natl Acad Sci USA. 2005; 102:16287–16292. [PubMed: 16251275]
- Albertson RC, Kocher TD. Genetic and developmental basis of cichlid trophic diversity. Heredity. 2006; 97:211–221. [PubMed: 16835594]
- Brem G, Brenig B, Hörstgen-Schwark G, Winnacker E. Gene transfer in tilapia (*Oreochromis niloticus*). Aquaculture. 1988; 68:209–219.
- Chourrout D, Guyomard R, Houdebine LM. High efficiency gene transfer in rainbow trout (*Salmo gairdneri* Rich.) by microinjection into egg cytoplasm. Aquaculture. 1986; 51:143–150.
- Farlora R, Kobayashi S, França LR, Batlouni SR, Lacerda SMSN, Yoshizaki G. Expression of GFP in transgenic tilapia under the control of the medaka β-actin promoter: establishment of a model system for germ cell transplantation. Anim Reprod. 2009; 6:450–459.
- Farrell JF, Campana SE. Regulation of Calcium and Strontium deposition on the otoliths of juvenile tilapia, *Oreochromis niloticus*. Comp Biochem Physiol. 1996; 115A:103–109.
- Fisher S, Grice EA, Vinton RM, Bessling SL, Urasaki A, Kawakami K, McCallion AS. Evaluating the biological relevance of putative enhancers using *Tol2* transposon-mediated transgensis in zebrafish. Nature Prot. 2006; 1:1297–1305.
- Food and Agriculture Organization (FAO). The State of World Fisheries and Aquaculture. Rome, Italy: 2008. Available from URL: http://www.fao.org/fishery/sofia/en
- Fryer, G.; Iles, T. The Cichlid Fishes of the Great Lakes of Africa. Oliver & Boyd; Edinburgh: 1972.
- Fujimura K, Okada N. Development of the embryo, larva and early juvenile of Nile tilapia Oreochromis niloticus (Pisces: Cichlidae). Developmental staging system. Dev Growth Differ. 2007; 49:301–324. [PubMed: 17501907]
- Fujimura K, Okada N. Bone development in the jaw of Nile tilapia *Oreochromis niloticus* (Pisces: Cichlidae). Dev Growth Differ. 2008a; 50:339–355. [PubMed: 18430028]
- Fujimura K, Okada N. Shaping of the lower jaw bone during growth of Nile tilapia Oreochromis niloticus and a Lake Victoria cichlid Haplochromis chilotes: a geometric morphometric approach. Dev Growth Differ. 2008b; 50:653–663. [PubMed: 18707606]
- Hofmann CM, O'Quin KE, Marshall NJ, Cronin TW, Seehausen O, Carleton KL. The eyes have it: regulatory and structural changes both underlie cichlid visual pigment diversity. PLoS Biol. 2009; 7:e1000266. [PubMed: 20027211]
- Ivics Z, Li MA, Mates L, Boeke JD, Nagy A, Bradley A, Izsvak Z. Transposon-mediated genome manipulation in vertebrates. Nature Methods. 2009; 6:415–422. [PubMed: 19478801]

- Johnson Hamlet MR, Yergeau DA, Kuliyev E, Takeda M, Taira M, Kawakami K, Mead PE. *Tol2* transposon-mediated transgenesis in *Xenopus tropicalis*. Genesis. 2006; 44:438–445. [PubMed: 16906529]
- Katagiri T, Kidd C, Tomasino E, Davis JT, Wishon C, Stern JE, Carleton KL, Howe AE, Kocher TD. A BAC-based physical map of the Nile tilapia genome. BMC Genomics. 2005; 6:89. [PubMed: 15946383]
- Kawakami K. Transgenesis and gene trap methods in zebrafish by using the *Tol2* transposable element. Meth Cell Biol. 2004; 77:201–222.
- Kawakami K. *Tol2*: a versatile gene transfer vector in vertebrates. Genome Biol. 2007; 8:S7. [PubMed: 18047699]
- Kawakami K, Koga A, Hori H, Shima A. Excision of the *Tol2* transposable element of the medaka fish, *Oryzias latipes*, in zebrafish, *Danio rerio*. Gene. 1998; 225:17–22. [PubMed: 9931412]
- Kawakami K, Shima A. Identification of the *Tol2* transposase of the medaka fish *Oryzias latipes* that catalyzes excision of a nonautonomous *Tol2* element in zebrafish *Danio rerio*. Gene. 1999; 240:239–244. [PubMed: 10564832]
- Kawakami K, Shima A, Kawakami N. Identification of a functional transposase of the *Tol2* element, an Ac-like element from the Japanese medaka fish, and its transposition in the zebrafish germ lineage. Proc Natl Acad Sci USA. 2000; 97:11403–11408. [PubMed: 11027340]
- Kawakami K, Takeda H, Kawakami N, Kobayashi M, Matsuda N, Mishina M. A transposon-mediated gene trap approach identifies developmentally regulated genes in zebrafish. Dev Cell. 2004; 7:133–144. [PubMed: 15239961]
- Kijimoto T, Watanabe M, Fujimura K, Nakazawa M, Murakami Y, Kuratani S, Kohara Y, Gojobori T, Okada N. *cimp1*, a novel astacin family metalloproteinase gene from East African cichlids, is differentially expressed between species during growth. Mol Biol Evol. 2005; 22:1649–1660. [PubMed: 15858202]
- Kinoshita M, Kani S, Ozato K, Wakamatsu Y. Activity of the medaka translation elongation factor lalpha-A promoter examined using the GFP gene as a reporter. Dev Growth Differ. 2000; 42:469– 478. [PubMed: 11041488]
- Kobayashi S, Alimuddin, Morita T, Miwa M, Lu L, Endo M, Takeuchi T, Yoshizaki G. Transgenic Nile tilapia (*Oreochromis niloticus*) over-expressing growth hormone show reduced ammonia excretion. Aquaculture. 2007; 270:427–435.
- Kocher TD. Adaptive evolution and explosive speciation: the cichlid fish model. Nature Rev Genet. 2004; 5:288–298. [PubMed: 15131652]
- Kocher TD, Lee WJ, Sobolewska H, Penman D, McAndrew B. A genetic linkage map of a cichlid fish, the Tilapia (*Oreochromis niloticus*). Genetics. 1998; 148:1225–1232. [PubMed: 9539437]
- Koga A, Suzuki M, Inagaki H, Bessho Y, Hori H. Transposable element in fish. Nature. 1996; 383:30. [PubMed: 8779712]
- Lee BY, Lee WJ, Streelman JT, Carleton KL, Howe AE, Hulata G, Slettan A, Stern JE, Terai Y, Kocher TD. A second-generation genetic linkage map of tilapia (*Oreochromis* spp.). Genetics. 2005; 170:237–244. [PubMed: 15716505]
- Maclean N, Rahman MA, Sohm F, Hwang G, Iyengar A, Ayad H, Smith A, Farahmand H. Transgenic tilapia and the tilapia genome. Gene. 2002; 295:265–277. [PubMed: 12354662]
- Majumdar KC, McAndrew BJ. Relative DNA content of somatic nuclei and chromosomal studies in three genera, *Tilapia*, *Sarotherodon*, and *Oreochromis* of the tribe Tilapiini (Pisces, Cichlidae). Genetica. 1986; 68:175–188.
- McCormick SD, Hasegawa S, Hirano T. Calcium uptake in the skin of a freshwater teleost. Proc Natl Acad Sci USA. 1992; 89:3635–3638. [PubMed: 1565659]
- Negrutskii BS, Elskaya AV. Eukaryotic translation elongation factor 1: Structure, expression, functions, and possible role in aminoacyl-tRNA channeling. Prog Nucleic Acids Res. 1998; 60:47–78.
- Oliveira C, Wright JM. Molecular cytogenetic analysis of heterochromatin in the chromosomes of tilapia, *Oreochromis niloticus* (Teleostei: Cichlidae). Chromosome Res. 1998; 6:205–211. [PubMed: 9609664]

- Parhar IS, Soga T, Sakuma Y. Thyroid hormone and estrogen regulate brain region- specific messenger ribonucleic acids encoding three gonadotropin-releasing hormone genes in sexually immature male fish, *Oreochromis niloticus*. Endocrinology. 2000; 141:1618–1625. [PubMed: 10803569]
- Rahman MA, Maclean N. Production of transgenic tilapia (*Oreochromis niloticus*) by one-cell-stage microinjection. Aquaculture. 1992; 105:219–232.
- Rahman MA, Iyengar A, Maclean N. Co-injection strategy improves integration efficiency of a growth hormone gene construct, resulting in lines of transgenic tilapia (*Oreochromis niloticus*) expressing an exogenous growth hormone gene. Transgenic Res. 1997; 6:369–378.
- Rahman MA, Mak R, Ayad H, Smith A, Maclean N. Expression of a novel piscine growth hormone gene results in growth enhancement in transgenic tilapia (*Oreochromis niloticus*). Transgenic Res. 1998; 7:357–369. [PubMed: 9859224]
- Rahman MA, Hwang GL, Razak SA, Sohm F, Maclean N. Copy number related transgene expression and mosaic somatic expression in hemizygous and homozygous transgenic tilapia (*Oreochromis niloticus*). Transgenic Res. 2000; 9:417–427. [PubMed: 11206970]
- Roberts RB, Ser J, Kocher TD. Sexual conflict resolved by invasion of a novel sex determiner in Lake Malawi cichlids. Science. 2009; 326:998–1001. [PubMed: 19797625]
- Santini S, Bernardi G. Organization and base composition of tilapia Hox genes: implications for the evolution of Hox clusters in fish. Gene. 2005; 346:51–61. [PubMed: 15716008]
- Strüssmann CA, Nakamura M. Morphology, endocrinology, and environmental modulation of gonadal sex differentiation in teleost fishes. Fish Physiol Biochem. 2002; 26:13–29.
- Udvadia AJ, Linney E. Windows into development: historic, current, and future perspectives on transgenic zebrafish. Dev Biol. 2003; 256:1–17. [PubMed: 12654288]
- Urasaki A, Morvan G, Kawakami K. Functional dissection of the *Tol2* transposable element identified the minimal cis-sequence and a highly repetitive sequence in the subterminal region essential for transposition. Genetics. 2006; 174:639–649. [PubMed: 16959904]
- Urasaki A, Mito T, Noji S, Ueda R, Kawakami K. Transposition of the vertebrate *Tol2* transposable element in *Drosophila melanogaster*. Gene. 2008; 425:64–68. [PubMed: 18775483]
- Wilson C, Bellen HJ, Gehring WJ. Position effects on eukaryotic gene expression. Ann Rev Cell Biol. 1990; 6:679–714. [PubMed: 2275824]



Fig.1.

GFP expression in the G₀ embryos, into which the plasmid was injected without (**a**, **b**) and with (**c**, **d**) transposase mRNA, at Stage 15 (4 dpf, 72 hpf). Lateral views of embryos. Left side (**a**, **c**), views on dark field. Right side (**b**, **d**), views through GFP filter. (**a**, **b**) No GFP expression was observed in the transposase (-) embryos. (**c**, **d**) Mosaic GPF expression was observed along the entire body in the transposase (+) embryos. Scale bar, 1 mm.



Fig.2.

Variation in intensity of GFP expression in the G₁ embryos. Stage 17 (5 dpf, 98 hpf). Lateral views of embryos. Left side (**a**, **c**, **e**, **g**), views on dark field. Right side (**b**, **d**, **f**, **h**), views through GFP filter. (**a**, **b**) Example of strong and ubiquitous GFP expression (GFP ++). (**c**, **d**, **e**, **f**) Examples of weak or mosaic GFP expression (GFP +). (**g**, **h**) Example of no GFP expression (GFP -). Scale bar, 1 mm.



Fig.3.

GFP expression in the GFP ++ of G_1 embryos during development from 1 to 3 days postfertilization. Left side (**a**, **c**, **e**), views on dark field. Right side (**b**, **d**, **f**), views through GFP filter. (**a**, **b**) Stage 1 (1 dpf, 1 hpf). Lateral views of one-cell egg. Animal pole at the top. GFP expression was observed in the cell. (**c**, **d**) Stage 9 (2 dpf, 27 hpf). Dorsal views of the embryo. GFP expression was observed in the cells of 40% epiboly, especially strong in the cells forming embryonic shield. (**e**, **f**) Stage 12 (3 dpf, 46 hpf). Dorsal views of the embryo. GFP expression was observed in the entire body of embryo. About ten somites form along the body axis. Scale bar, 1 mm.



Fig.4.

GFP expression in the GFP ++ of G₁ embryos during development from 4 to 8 days postfertilization. Lateral views of embryos through GFP filter. (a) Stage 15 (4 dpf, 74 hpf). (b) Stage 17 (5 dpf, 100 hpf). (c) Stage 18 (6 dpf, 122 hpf). (d) Stage 19 (7 dpf, 143 hpf). (e) Stage 21 (8 dpf, 171hpf). Arrows indicate 'undifferentiated white tissue' (Fujimura and Okada 2007). Scale bar, 1 mm.

Table 1

GFP positive rate in G₁ clutches

Mother	Clutch ID	GFP+	GFP-	GFP Rate
TG14-1	#307	38	93	29.0%
	#312	126	381	24.9%
	#327	158	423	27.2%
	#332	111	340	24.6%
TG14-2	#329	96	239	28.7%
TG14-3	#311	132	318	29.3%
	#333	159	201	44.2%
Total		820	1995	29.1%

The number of embryos with and without GFP signals was counted in each clutch from crossing eggs from G₀ transgenic females and sperm from wild type males.